Publicacións en colaboración con investigadores/as de New York University School of Medicine (23)

2024

  1. Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4

    Journal of Cardiac Failure

  2. Fine-mapping analysis including over 254,000 East Asian and European descendants identifies 136 putative colorectal cancer susceptibility genes

    Nature Communications, Vol. 15, Núm. 1

  3. Global Longitudinal Strain as Predictor of Inducible Ischemia in No Obstructive Coronary Artery Disease in the CIAO-ISCHEMIA Study

    Journal of the American Society of Echocardiography, Vol. 37, Núm. 1, pp. 89-99

  4. Ischemia Severity, Coronary Artery Disease Extent, and Exercise Capacity in ISCHEMIA

    Circulation, Vol. 150, Núm. 2, pp. 165-167

  5. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

    Journal of Extracellular Vesicles, Vol. 13, Núm. 2

  6. Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM

    Journal of the American College of Cardiology, Vol. 84, Núm. 19, pp. 1839-1849

2023

  1. Author Correction: Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries (Nature Genetics, (2023), 55, 1, (89-99), 10.1038/s41588-022-01222-9)

    Nature Genetics

  2. Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries

    Nature Genetics, Vol. 55, Núm. 1, pp. 89-99

  3. Impact of Complete Revascularization in the ISCHEMIA Trial

    Journal of the American College of Cardiology, Vol. 82, Núm. 12, pp. 1175-1188

  4. Survival after Invasive or Conservative Management of Stable Coronary Disease

    Circulation, Vol. 147, Núm. 1, pp. 8-19

2022

  1. Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial

    American Heart Journal, Vol. 248, pp. 72-83

  2. Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial

    European heart journal, Vol. 43, Núm. 2, pp. 148-149

  3. Outcomes With Intermediate Left Main Disease: Analysis From the ISCHEMIA Trial

    Circulation: Cardiovascular Interventions, Vol. 15, Núm. 4, pp. E010925

  4. Predictors of Left Main Coronary Artery Disease in the ISCHEMIA Trial

    Journal of the American College of Cardiology, Vol. 79, Núm. 7, pp. 651-661

2021

  1. Comparison of Days Alive out of Hospital with Initial Invasive vs Conservative Management: A Prespecified Analysis of the ISCHEMIA Trial

    JAMA Cardiology, Vol. 6, Núm. 9, pp. 1023-1031

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  3. Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel

    Alzheimer's and Dementia, Vol. 17, Núm. 9, pp. 1528-1553

2020

  1. Initial invasive or conservative strategy for stable coronary disease

    New England Journal of Medicine, Vol. 382, Núm. 15, pp. 1395-1407

2018

  1. High-resolution Imaging of Myeloperoxidase Activity Sensors in Human Cerebrovascular Disease

    Scientific Reports, Vol. 8, Núm. 1

2016

  1. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy